52
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Conveying Equipoise during Recruitment for Clinical Trials: Qualitative Synthesis of Clinicians’ Practices across Six Randomised Controlled Trials

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Randomised controlled trials (RCTs) are essential for evidence-based medicine and increasingly rely on front-line clinicians to recruit eligible patients. Clinicians’ difficulties with negotiating equipoise is assumed to undermine recruitment, although these issues have not yet been empirically investigated in the context of observable events. We aimed to investigate how clinicians conveyed equipoise during RCT recruitment appointments across six RCTs, with a view to (i) identifying practices that supported or hindered equipoise communication and (ii) exploring how clinicians’ reported intentions compared with their actual practices.

          Methods and Findings

          Six pragmatic UK-based RCTs were purposefully selected to include several clinical specialties (e.g., oncology, surgery) and types of treatment comparison. The RCTs were all based in secondary-care hospitals ( n = 16) around the UK. Clinicians recruiting to the RCTs were interviewed ( n = 23) to understand their individual sense of equipoise about the RCT treatments and their intentions for communicating equipoise to patients. Appointments in which these clinicians presented the RCT to trial-eligible patients were audio-recorded ( n = 105). The appointments were analysed using thematic and content analysis approaches to identify practices that supported or challenged equipoise communication. A sample of appointments was independently coded by three researchers to optimise reliability in reported findings. Clinicians and patients provided full written consent to be interviewed and have appointments audio-recorded.

          Interviews revealed that clinicians’ sense of equipoise varied: although all were uncertain about which trial treatment was optimal, they expressed different levels of uncertainty, ranging from complete ambivalence to clear beliefs that one treatment was superior. Irrespective of their personal views, all clinicians intended to set their personal biases aside to convey trial treatments neutrally to patients (in accordance with existing evidence). However, equipoise was omitted or compromised in 48/105 (46%) of the recorded appointments. Three commonly recurring practices compromised equipoise communication across the RCTs, irrespective of clinical context. First, equipoise was overridden by clinicians offering treatment recommendations when patients appeared unsure how to proceed or when they asked for the clinician’s expert advice. Second, clinicians contradicted equipoise by presenting imbalanced descriptions of trial treatments that conflicted with scientific information stated in the RCT protocols. Third, equipoise was undermined by clinicians disclosing their personal opinions or predictions about trial outcomes, based on their intuition and experience. These broad practices were particularly demonstrated by clinicians who had indicated in interviews that they held less balanced views about trial treatments. A limitation of the study was that clinicians volunteering to take part in the research might have had a particular interest in improving their communication skills. However, the frequency of occurrence of equipoise issues across the RCTs suggests that the findings are likely to be reflective of clinical recruiters’ practices more widely.

          Conclusions

          Communicating equipoise is a challenging process that is easily disrupted. Clinicians’ personal views about trial treatments encroached on their ability to convey equipoise to patients. Clinicians should be encouraged to reflect on personal biases and be mindful of the common ways in which these can arise in their discussions with patients. Common pitfalls that recurred irrespective of RCT context indicate opportunities for specific training in communication skills that would be broadly applicable to a wide clinical audience.

          Abstract

          In a qualitative synthesis from six randomized controlled trials, Leila Rooshenas and colleagues examine how clinicians convey equipoise during recruitment for clinical trials.

          Author Summary

          Why Was This Study Done?
          • Randomised controlled trials (RCTs) are a cornerstone of evidence-based medicine, but they need to recruit sufficient numbers of patients if they are to provide answers to the clinical questions they intend to address.

          • Front-line clinicians are increasingly responsible for recruiting patients into RCTs, but there are questions around how they reconcile their own views about RCT treatments with the requirement to convey “equipoise” to patients (the principle that the patient would be neither advantaged nor disadvantaged if they were to receive any of the trial treatments under investigation).

          • Clinicians’ attempts to communicate equipoise have not yet been investigated in the context of real doctor–patient interactions, and there are no evidence-based recommendations for how clinicians should convey equipoise to patients who are eligible for RCT participation.

          What Did the Researchers Do and Find?
          • We aimed to investigate how clinicians attempted to communicate equipoise to patients across six RCTs, with the objectives of (i) identifying broad practices that support or hinder equipoise communication and (ii) examining how these practices compare with clinicians’ intentions.

          • We interviewed clinicians ( n = 23) to understand their intentions for communicating equipoise to patients, and audio-recorded their discussions (“appointments”) with RCT-eligible patients ( n = 105) to investigate their actual practices.

          • Despite clinicians’ best intentions, equipoise communication was omitted or undermined in almost half of the appointments ( n = 48) through commonly recurring practices that were apparent across the RCTs, including (i) offering treatment recommendations, (ii) providing imbalanced descriptions of trial treatments, and (iii) disclosing personal predictions about RCT outcomes.

          What Do These Findings Mean?
          • Communicating equipoise to patients is a delicate process that can be overridden or undermined through commonly recurring practices that emerge irrespective of clinical context.

          • There are opportunities to create generic guidance for clinicians based on these common challenges, with a view to facilitating the communication of equipoise to RCT-eligible patients.

          • Our findings were limited by our intentional focus on RCTs that were anticipated to experience recruitment difficulties, and thus this issue needs further consideration in RCTs that are deemed less challenging to recruit patients into.

          Related collections

          Most cited references42

          • Record: found
          • Abstract: found
          • Article: not found

          Prevalence, characteristics, and publication of discontinued randomized trials.

          The discontinuation of randomized clinical trials (RCTs) raises ethical concerns and often wastes scarce research resources. The epidemiology of discontinued RCTs, however, remains unclear. To determine the prevalence, characteristics, and publication history of discontinued RCTs and to investigate factors associated with RCT discontinuation due to poor recruitment and with nonpublication. Retrospective cohort of RCTs based on archived protocols approved by 6 research ethics committees in Switzerland, Germany, and Canada between 2000 and 2003. We recorded trial characteristics and planned recruitment from included protocols. Last follow-up of RCTs was April 27, 2013. Completion status, reported reasons for discontinuation, and publication status of RCTs as determined by correspondence with the research ethics committees, literature searches, and investigator surveys. After a median follow-up of 11.6 years (range, 8.8-12.6 years), 253 of 1017 included RCTs were discontinued (24.9% [95% CI, 22.3%-27.6%]). Only 96 of 253 discontinuations (37.9% [95% CI, 32.0%-44.3%]) were reported to ethics committees. The most frequent reason for discontinuation was poor recruitment (101/1017; 9.9% [95% CI, 8.2%-12.0%]). In multivariable analysis, industry sponsorship vs investigator sponsorship (8.4% vs 26.5%; odds ratio [OR], 0.25 [95% CI, 0.15-0.43]; P < .001) and a larger planned sample size in increments of 100 (-0.7%; OR, 0.96 [95% CI, 0.92-1.00]; P = .04) were associated with lower rates of discontinuation due to poor recruitment. Discontinued trials were more likely to remain unpublished than completed trials (55.1% vs 33.6%; OR, 3.19 [95% CI, 2.29-4.43]; P < .001). In this sample of trials based on RCT protocols from 6 research ethics committees, discontinuation was common, with poor recruitment being the most frequently reported reason. Greater efforts are needed to ensure the reporting of trial discontinuation to research ethics committees and the publication of results of discontinued trials.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Varieties of Uncertainty in Health Care

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              The intellectual challenges and emotional consequences of equipoise contributed to the fragility of recruitment in six randomized controlled trials☆

              Objective The aim of the study was to investigate how doctors considered and experienced the concept of equipoise while recruiting patients to randomized controlled trials (RCTs). Study Design and Setting In-depth interviews with 32 doctors in six publicly funded pragmatic RCTs explored their perceptions of equipoise as they undertook RCT recruitment. The RCTs varied in size, duration, type of complex intervention, and clinical specialties. Interview data were analyzed using qualitative content and thematic analytical methods derived from grounded theory and synthesized across six RCTs. Results All six RCTs suffered from poor recruitment. Doctors wanted to gather robust evidence but experienced considerable discomfort and emotion in relation to their clinical instincts and concerns about patient eligibility and safety. Although they relied on a sense of community equipoise to justify participation, most acknowledged having “hunches” about particular treatments and patients, some of which undermined recruitment. Surgeons experienced these issues most intensely. Training and support promoted greater confidence in equipoise and improved engagement and recruitment. Conclusion Recruitment to RCTs is a fragile process and difficult for doctors intellectually and emotionally. Training and support can enable most doctors to become comfortable with key RCT concepts including equipoise, uncertainty, patient eligibility, and randomization, promoting a more resilient recruitment process in partnership with patients.
                Bookmark

                Author and article information

                Contributors
                Role: Academic Editor
                Journal
                PLoS Med
                PLoS Med
                plos
                plosmed
                PLoS Medicine
                Public Library of Science (San Francisco, CA USA )
                1549-1277
                1549-1676
                18 October 2016
                October 2016
                : 13
                : 10
                : e1002147
                Affiliations
                [1 ]School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
                [2 ]Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
                [3 ]Rosemere Cancer Centre, Royal Preston Hospital, Preston, United Kingdom
                [4 ]St George’s, University of London, London, United Kingdom
                [5 ]Clinical Trials and Evaluation Unit, Bristol Royal Infirmary, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom
                [6 ]University College London Hospitals, London, United Kingdom
                [7 ]National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care West (NIHR CLAHRC West), University Hospitals Bristol NHS Trust, Bristol, United Kingdom
                Stanford University, UNITED STATES
                Author notes

                The authors have declared that no competing interests exist. The authors declare no support from any organisation for the submitted work beyond those funding bodies declared in the manuscript.

                • Conceptualization: JLD.

                • Data curation: LR.

                • Formal analysis: LR DE JW JLD.

                • Funding acquisition: DB JMB AB AH CAR RS JLD.

                • Investigation: LR DE MJ SP SS CW DB JMB AB AH CAR RS JLD.

                • Methodology: JLD.

                • Project administration: DB JMB AB AH CAR RS JLD.

                • Supervision: JLD.

                • Validation: LR DE JW JLD.

                • Writing – original draft: LR JLD.

                • Writing – review & editing: LR DE JW MJ SP SS CW DB JMB AB AH CAR RS JLD.

                ¶ Membership of the ACST-2 study group, By-Band-Sleeve study group, Chemorad study group, CSAW study group, Optima prelim study group, and POUT study group is provided in the Acknowledgments.

                Author information
                http://orcid.org/0000-0002-6166-6055
                http://orcid.org/0000-0001-7329-9574
                http://orcid.org/0000-0002-9624-2615
                http://orcid.org/0000-0003-2969-0415
                http://orcid.org/0000-0002-6488-5472
                Article
                PMEDICINE-D-16-01729
                10.1371/journal.pmed.1002147
                5068710
                27755555
                f07c460e-b94c-4fab-8b56-8f5ca955c6e8
                © 2016 Rooshenas et al

                This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 1 June 2016
                : 7 September 2016
                Page count
                Figures: 1, Tables: 2, Pages: 24
                Funding
                Funded by: funder-id http://dx.doi.org/10.13039/501100000664, Health Technology Assessment Programme;
                Award ID: HTA 96/20/06, HTA 96/20/99
                Award Recipient :
                Funded by: funder-id http://dx.doi.org/10.13039/501100000265, Medical Research Council;
                Award ID: MR/K025643/1
                Award Recipient :
                Funded by: funder-id http://dx.doi.org/10.13039/501100000664, Health Technology Assessment Programme;
                Award ID: HTA 06/301/233
                Award Recipient :
                Funded by: funder-id http://dx.doi.org/10.13039/501100000664, Health Technology Assessment Programme;
                Award ID: HTA 09/127/53
                Award Recipient :
                Funded by: funder-id http://dx.doi.org/10.13039/501100000341, Arthritis Research UK;
                Award ID: 19707
                Award Recipient :
                Funded by: funder-id http://dx.doi.org/10.13039/501100000272, National Institute for Health Research;
                Award ID: PB-PG-0807-14131
                Award Recipient :
                Funded by: funder-id http://dx.doi.org/10.13039/501100000289, Cancer Research UK;
                Award ID: CRUK/11/027
                Award Recipient :
                Funded by: funder-id http://dx.doi.org/10.13039/501100000664, Health Technology Assessment Programme;
                Award ID: HTA 10/34/01
                Award Recipient :
                This investigation was supported by the Medical Research Council (MRC) ( http://www.mrc.ac.uk/) Collaboration and Innovation for Difficult Trials in Invasive procedures (ConDuCT-II) Hub for Trials Methodology Research (MR/K025643/1). The funding sources for the recruitment sub-studies that informed this synthesis are, listed by RCT (in alphabetical order): Acst-2—National Institute for Health Research (NIHR) ( http://www.nihr.ac.uk/) Health Technology Assessment (HTA)(HTA 06/301/233) and the Bupa Foundation; By-Band-Sleeve—NIHR HTA (HTA 09/127/53); CSAW—Arthritis Research UK ( http://www.arthritisresearchuk.org/) (19707); Feasibility RCT of definitive chemoradiotherapy or chemotherapy and surgery for oesophageal squamous cell cancer—NIHR Research for Patient Benefit (RfPB) (PB-PG-0807-14131); POUT—Cancer Research UK (CRUK) ( http://www.cancerresearchuk.org/)(CRUK/11/027); Optima prelim: NIHR HTA (HTA 10/34/01). JW was funded by the NIHR HTA Programme (Projects No. HTA 96/20/06, HTA 96/20/99; ISRCTN20141297) during the period when this study was conducted. JLD was supported by the NIHR Collaboration for Leadership in Applied Health Research and Care (CLAHRC) West at University Hospitals Bristol NHS Foundation Trust and an NIHR Senior Investigator award. JMB is supported by an NIHR Senior Investigator award. This article presents independent research funded by NIHR, Arthritis Research UK, CRUK, and the MRC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
                Categories
                Research Article
                Medicine and Health Sciences
                Clinical Medicine
                Clinical Trials
                Randomized Controlled Trials
                Medicine and Health Sciences
                Pharmacology
                Drug Research and Development
                Clinical Trials
                Randomized Controlled Trials
                Research and Analysis Methods
                Clinical Trials
                Randomized Controlled Trials
                Medicine and Health Sciences
                Oncology
                Cancer Treatment
                Surgical Oncology
                Medicine and Health Sciences
                Clinical Medicine
                Clinical Oncology
                Surgical Oncology
                Medicine and Health Sciences
                Oncology
                Clinical Oncology
                Surgical Oncology
                Medicine and Health Sciences
                Oncology
                Cancer Treatment
                Medicine and Health Sciences
                Surgical and Invasive Medical Procedures
                Medicine and Health Sciences
                Health Care
                Health Services Research
                Medicine and Health Sciences
                Health Care
                Health Care Providers
                Nurses
                People and Places
                Population Groupings
                Professions
                Nurses
                Medicine and Health Sciences
                Surgical and Invasive Medical Procedures
                Cardiovascular Procedures
                Vascular Surgery
                Biology and Life Sciences
                Neuroscience
                Cognitive Science
                Cognition
                Decision Making
                Custom metadata
                The dataset (transcripts) informing this study are available on request, by contacting leila.rooshenas@ 123456bristol.ac.uk or carmel.conefrey@ 123456bristol.ac.uk . The data have not been uploaded to a public repository due to privacy concerns, but the authors will be able to consider specific requests on a case-by-case basis.

                Medicine
                Medicine

                Comments

                Comment on this article